NASDAQ:HSCS HeartSciences Q4 2025 Earnings Report $4.30 +0.41 (+10.54%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$4.31 +0.01 (+0.21%) As of 10/2/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast HeartSciences EPS ResultsActual EPS-$1.88Consensus EPS -$2.51Beat/MissBeat by +$0.63One Year Ago EPSN/AHeartSciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHeartSciences Announcement DetailsQuarterQ4 2025Date7/24/2025TimeAfter Market ClosesConference Call DateThursday, July 24, 2025Conference Call Time8:00AM ETUpcoming EarningsHeartSciences' Q2 2027 earnings is estimated for Monday, December 21, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, December 16, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) HeartSciences Earnings HeadlinesHeartSciences Extends Loan Terms Amid Pending MergerOctober 2 at 6:10 PM | tipranks.comFortitude Appoints Kimberly Pittman as Chief Legal OfficerSeptember 29, 2026 | marketscreener.comMDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 3 at 1:00 AM | Stansberry Research (Ad)HeartSciences' Merger Partner Fortitude Upsizes DCG Credit Facility to $50 MillionSeptember 24, 2026 | finance.yahoo.comFortitude Announces Amendment to Existing DCG Credit Facility, Increasing Commitment by $24 Million and Providing for Future Funding in ZECSeptember 23, 2026 | marketscreener.comMHeartSciences FQ1 Loss Widens; MyoVista Gains Traction, Fortitude Deal AdvancesSeptember 15, 2026 | rttnews.comSee More HeartSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email. Email Address About HeartSciencesHeartSciences (NASDAQ:HSCS), Inc. is a medical technology company focused on improving the detection and management of cardiovascular disease. The company develops electrocardiography (ECG) technologies intended to provide clinicians with additional information about cardiac function using a test that is widely available in healthcare settings. Its principal technology is the MyoVista wavECG system, which applies proprietary signal-processing methods, including wavelet analysis, to standard 12-lead ECG data. The platform is designed to identify indicators of cardiac dysfunction, including abnormalities associated with diastolic dysfunction, and to support physicians in evaluating patients for potential heart disease. HeartSciences markets its products to healthcare providers and is pursuing applications across cardiology, primary care and other clinical settings. The company was previously known as Heart Test Laboratories and trades on the Nasdaq under the symbol HSCS. Its corporate operations are based in the United States, with its technologies intended for use in domestic and international healthcare markets.View HeartSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
